{
  "response": "The clinical trial that best describes the efficacy of enzalutamide monotherapy compared to placebo in treating prostate cancer is identified by the ClinicalTrials.gov number NCT02319837. This Phase 3 study, known as the EMBARK trial, evaluated enzalutamide monotherapy in patients with high-risk biochemical recurrence of prostate cancer. The results demonstrated that enzalutamide monotherapy significantly delayed metastasis-free survival compared to placebo plus leuprolide acetate. ([oncologypro.esmo.org](https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/enzalutamide-enza-monotherapy-for-the-treatment-tx-of-prostate-cancer-with-high-risk-biochemical-recurrence-bcr-embark-secondary-endpoints?utm_source=openai)) "
}